Effectiveness of GV20-based wearable low-level laser acupoint therapy for pain on head
Abstract
The effectiveness of GV20-based Wearable Low-level Laser Acupoint Therapy for pain on right temporal head was investigated. The study was designed as a triple-blinded, randomized controlled clinical trial. The deep pressure pain targeted by 300g monofilament and Visual Analog Scale (VAS, 0-10) scores on right temporal head were assessed were randomly assigned to wearable LLLAT (650 nm, 5 mW, 30 min, about 9 joule each acupoint) on Baihui (GV20) with four Sishencong (EX-HN1) or sham group (n=24 vs 24). The mean VAS pain scores in wearable LLLAT group after GV20 with EX-HN1 acupoint treatment were significantly decreased comparing with sham group. This trial suggested that wearable Low-level Laser Acupoint Therapy 650 nm 5 mW for 30 min each acupoint simultaneously could effectively reduce deep pressure pain on temporal head.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 24 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.